Business Wire

LINCOTEK

21.3.2022 14:02:44 CET | Business Wire | Press release

Share
Lincotek Acquires Majority Stake in Highly Automated Forging Facility

Global contract manufacturer Lincotek announced today that it has signed an agreement to acquire a majority stake in Italy-based Pegasus’ medical division. The Alaria family will remain fully involved in the business, with Alberto Alaria taking the position of Managing Director of the new entity.

The move will further strengthen the Medical Division of Lincotek Group , which is continuing its global investment program to respond to ever-more demanding customer requirements in terms of integrated solutions. Through new technologies and automation, the company is addressing the growing interest of the orthopedic device market in an automated forging service, increasing efficiency along the supply chain, setting new standards around quality and reliability and further reducing lead time.

The investment represents an important addition to an already comprehensive set of capabilities that Lincotek Medical has in-house and enhances the company’s competitive edge, adding unique, state-of- the-art capabilities in the forging field.

Established in 2007 in Torino, northern Italy, Pegasus decided in 2019 to expand its innovative forging processes into the medical market. The brand-new facility - with a surface area of around 3,000 sqm - is completely dedicated to orthopedic applications, being ISO 13485 certified and having an ISO 17025 certified internal laboratory. Lincotek’s forging offers a unique level of automation through the manufacturing process ensuring state-of-the-art product quality, total process control and repeatability.

The fully robotized forging line - which allows the manufacture of high-quality forged implantable parts to customer specifications – is the flagship of a complete production service of forged components. Its capabilities are combined with a state-of-the-art, AMS-2750-compliant heat treatment furnace ; automated pickling line and liquid penetrant inspection unit ; laboratory equipment; internal mold manufacturing; robotized deburring and polishing unit; and computerized dimensional control.

Lincotek Medical will therefore offer a new, impressive, high-volume capacity, through single service or fully-integrated solutions to support OEMs with a strategic long-term partnership.

Winfried Schaller, CEO of Lincotek Group commented: “With the acquisition of the majority stake in Pegasus medical division, Lincotek Medical is in a stronger position than ever before to support orthopedic OEMs. By combining this impressive forging service with our existing offering, we are able to help customers stay competitive and get to market even faster. It really is a new world of advanced automation and productivity.”

Speaking for Pegasus, Alberto Alaria, the company’s Managing Director, said: “Pegasus is proud to enter into partnership with Lincotek Group which represents a great opportunity to grow our presence in the forged medical implants market with the offering of high-quality products. The new synergies and product integration that will be generated moves us a step ahead and creates the possibility of further strengthening the cooperation with our valued customers.”

Bringing this full suite of processes in-house, orthopedic OEMs can now rely on a well-established partner, which has broad capabilities and brings together the core competencies of R&D, product design, regulatory affairs, and manufacturing all under one roof, keeping focus on their core competencies.

About Lincotek

Lincotek, headquartered in Rubbiano, Parma - Italy, is a global contract manufacturer for services in niche markets including Industrial Gas Turbines, Aviation and Medical Device applications, as well as a leading manufacturer of industrial coating equipment and one of the most respected producers in the Additive Manufacturing field. The Group is family-owned and has more than 1,300 employees located in 17 production facilities across Europe, North America and Asia.

About Pegasus

Established in Favria, Torino (Italy) in 2007 on a 100,000 sqm site, of which 20,000 is covered, PEGASUS has forging, heat treating, machining and NDT inspection capabilities for the production of forged and rolled components for Industrial and Medical purposes.

For more information, please visit lincotek.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye